Stock Events

Stock Events

Pulmatrix 

$1.3900
29
+$0.03+2.21% Friday 20:00
+$0.06+4.32%Friday 22:55After hours

Statistics

Day High
1.39
Day Low
1.39
52W High
5.5
52W Low
1.16
Volume
213
Avg. Volume
-
Mkt Cap
5.08M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Next
-0.55
-0.45
-0.34
-0.24
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-5.16MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PULM. It's not an investment recommendation.
AMD
7
AMD
Tesla
5
TSLA
NIO
5
NIO
Plug Power
5
PLUG

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals focuses on developing inhalation therapies for cystic fibrosis, directly competing with Pulmatrix's respiratory disease treatments.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline produces a range of respiratory products, including treatments for asthma and COPD, competing in the same market as Pulmatrix.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a strong portfolio in respiratory care, including treatments for asthma and COPD, making it a direct competitor to Pulmatrix.
Insmed
INSM
Mkt Cap25.89B
Insmed Incorporated specializes in rare lung diseases, offering products that compete with Pulmatrix's treatments for respiratory disorders.
Champion Industries
CHMP
Mkt Cap1,129
ChampionX Corporation, though not a direct pharmaceutical competitor, provides technologies and solutions that could indirectly compete with Pulmatrix's drug delivery technologies.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries has a broad portfolio that includes respiratory treatments, competing with Pulmatrix in the generic and specialty medicine sectors.
Novartis
NVS
Mkt Cap292.35B
Novartis offers a wide range of healthcare products, including treatments for respiratory conditions, making it a competitor in the broader healthcare market.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. develops medications for various conditions, including respiratory diseases, positioning it as a competitor in the pharmaceutical industry.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse portfolio of health care products, including treatments for respiratory conditions, competing across multiple segments with Pulmatrix.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on advanced therapies for serious diseases, including respiratory conditions, indirectly competing with Pulmatrix in the biopharmaceutical sector.

About

Pulmatrix Inc is a biopharmaceutical company focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Show more...
CEO
Peter Ludlum
Employees
2
Country
United States
ISIN
US74584P3010
WKN
000A3DWEE

Listings

MU
DE
2PU1.MU
F
DE
2PU.F
STU
DE
2PU.STU
XNAS
US
PULM

0 Comments

Share your thoughts

FAQ

What is Pulmatrix stock price today?▼
The current price of PULM is $1.39 USD — it has increased by +2.21% in the past 24 hours. Watch Pulmatrix stock price performance more closely on the chart.
What is Pulmatrix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Pulmatrix stocks are traded under the ticker PULM.
Is Pulmatrix stock price growing?▼
PULM stock has fallen by -7.95% compared to the previous week, the month change is a -15.76% fall, over the last year Pulmatrix has showed a -71.46% decrease.
What is Pulmatrix market cap?▼
Today Pulmatrix has the market capitalization of 5.08M
When is the next Pulmatrix earnings date?▼
Pulmatrix is going to release the next earnings report on November 05, 2026.
What is Pulmatrix revenue for the last year?▼
Pulmatrix revenue for the last year amounts to 0 USD.
What is Pulmatrix net income for the last year?▼
PULM net income for the last year is -5.16M USD.
How many employees does Pulmatrix have?▼
As of September 05, 2026, the company has 2 employees.
In which sector is Pulmatrix located?▼
Pulmatrix operates in the Health & Wellness sector.
When did Pulmatrix complete a stock split?▼
The last stock split for Pulmatrix was on March 01, 2022 with a ratio of 1:20.
Where is Pulmatrix headquartered?▼
Pulmatrix is headquartered in FRAMINGHAM, United States.